Smajilagic Amer, Al-Khalil Moustafa Y, Redjic Amira, Filipovic Selma, Hadjihasanovic Besima, Lappalainen Sami
Clinic for Maxillofacial Surgery, University Clinic Center Sarajevo, Porodice Ribara 91, Sarajevo, Bosnia and Herzegovina.
Saudi Med J. 2005 Sep;26(9):1398-402.
To obtain information on the feasibility of employing recombinant human bone morphogenetic protein-7 (rhBMP-7), mixed with bone marrow as a substitute for autologous bone graft.
We carried out the study in the University Clinic Center, Sarajevo, Bosnia and Herzegovina, from February 2002 to January 2004. Six New Zealand rabbits underwent hemiresection of the mandible. We placed rhBMP-7 in a concentration of 100 micrograms and collagen (ACS) as carrier mixed with bone marrow in the defects in 3 animals. In another group of 3, we restored the defect by placement of autologous bone graft harvested from the iliac crest. We evaluated the results by the activity of the alkaline phosphatase enzyme (ALP), CT assessment with bone mineral density (BMD) analysis, and clinical and histologic examinations.
The ALP activity was significantly higher after 14 days, in the rhBMP7/ACS sites than the bone graft sites (30th day). Mean BMD of tissue induced by rhBMP-7/ACS on the 30th day was 510 mg/cm3 in caudal, and 553 mg/cm3 in sagittal plane, and bone graft tissue was 510 mg/cm3 in caudal and 530 mg/cm3 in sagittal plane. Clinical inspection and histologic examination on the 60th day showed complete bridged defects with abundant woven bone in 2 of 3 rhBMP-7/ACS sites (67%), and no incorporation of the autologous bone graft into the other groups treated sites.
The rhBMP-7/ACS mixed with bone marrow was very effective in establishing complete bone regeneration into the defects, indicating that it could be an adequate alternative for autologous bone transplantation.
获取有关使用重组人骨形态发生蛋白-7(rhBMP-7)与骨髓混合作为自体骨移植替代物的可行性信息。
我们于2002年2月至2004年1月在波斯尼亚和黑塞哥维那萨拉热窝大学临床中心开展了该研究。六只新西兰兔接受了下颌骨半切除。在3只动物的缺损处植入浓度为100微克的rhBMP-7,并将胶原蛋白(ACS)作为载体与骨髓混合。在另一组3只动物中,通过植入从髂嵴获取的自体骨移植来修复缺损。我们通过碱性磷酸酶(ALP)活性、骨密度(BMD)分析的CT评估以及临床和组织学检查来评估结果。
rhBMP7/ACS组在14天后的ALP活性显著高于骨移植组(第30天)。rhBMP-7/ACS诱导的组织在第30天的尾侧平均骨密度为510毫克/立方厘米,矢状面为553毫克/立方厘米,而骨移植组织在尾侧为510毫克/立方厘米,矢状面为530毫克/立方厘米。第60天的临床检查和组织学检查显示,3个rhBMP-7/ACS位点中有2个(67%)完全桥接缺损,有大量编织骨,而其他组治疗位点的自体骨移植未融合。
rhBMP-7/ACS与骨髓混合在缺损处建立完全骨再生方面非常有效,表明它可能是自体骨移植的合适替代物。